SequelSEC

BioXcel Therapeutics, Inc. BTAI

Pharmaceutical Preparations · CIK 0001720893 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$742.00K
Fiscal year ended 2026-06-30
Operating income
-$44.93M
Fiscal year ended 2026-06-30
Free cash flow
-$50.90M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$11.02MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.41Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue17.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.0%0th
FCF margin-8974.3%9th
Net margin-10887.4%10th
R&D / revenue4712.0%89th
Operating margin-7860.0%13th
Current ratio0.83x14th
SBC / revenue431.0%85th
Revenue YoY growth-71.7%17th
Gross margin74.5%56th

BioXcel Therapeutics, Inc. (BTAI) reported revenue of $742.00K and net income of -$70.86M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BioXcel Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

BioXcel Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$742.00K
Cost of revenue$348.00K
Gross profit$394.00K
Operating income-$44.93M
Net income-$70.86M
Research & development$21.56M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$23.57M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

BioXcel Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$12.84M
Total assets$28.80M
Current assets$28.70M
Total liabilities$144.26M
Current liabilities$137.15M
Total equity incl. NCI-$115.46M
Temporary (mezzanine) equityUnavailable
Inventory$483.00K
Accounts receivable$82.00K
GoodwillUnavailable
Long-term debt$0
Accounts payable$18.78M

Cash flow

BioXcel Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$50.90M
Capital expenditures$0
Investing cash flow$0
Financing cash flow$46.13M
Net change in cash-$4.77M
Stock-based compensation$1.82M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

BioXcel Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$50.90M
Gross margin53.1%
Operating margin-6054.7%
FCF margin-6860.4%
SBC / revenue245.8%
Current ratio0.21x
Revenue YoY growth-14.5%
Net margin-9549.9%
R&D / revenue2905.7%
CapEx / revenue0.0%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BTAI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-27View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.